Regression After Whole-Brain Radiation Therapy for Brain Metastases Correlates With Survival and Improved Neurocognitive Function
Top Cited Papers
- 1 April 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (10) , 1260-1266
- https://doi.org/10.1200/jco.2006.09.2536
Abstract
Purpose: Brain metastasis (BM) is a major cause of suffering and health costs in cancer patients. Whole-brain radiation therapy (WBRT) offers tumor shrinking and palliation in many cases, but it has been speculated that these benefits may be outweighed by adverse effects on neurocognitive function (NCF). Patients and Methods: Two hundred eight BM patients from the WBRT arm of phase III trial PCI-P120-9801 evaluating motexafin gadolinium were analyzed. NCF, assessed by tests of memory, executive function, and fine motor coordination, was correlated to magnetic resonance imaging–measured BM volume. NCF and survival were compared in 135 patients assessable at 2 months with tumor shrinkage below (poor responders) and above (good responders) the population median (45%). Mean NCF scores and BM volume at 4 and 15 months were compared. Results: Good responders experienced a significantly improved survival (unidirectional P = .03). For all tests, the median time to NCF deterioration was longer in good compared with poor responders, with statistical significance seen for Trailmaking B (executive function), and two Pegboard tests (fine motor). In long-term survivors, tumor shrinkage significantly correlated with preservation of executive function and fine motor coordination (r = 0.68 to 0.88). During the early follow-up period, the population mean NCF scores were dominated by patients with progressive disease. A small subset of 15-month survivors had stable or improving scores, and greater mean BM reduction. Conclusion: WBRT-induced tumor shrinkage correlates with better survival and NCF preservation. NCF is stable or improved in long-term survivors. Tumor progression adversely affects NCF more than WBRT does, thus making enhancement of radiation response a worthwhile aim in this patient population.Keywords
This publication has 12 references indexed in Scilit:
- Role and Relevance of Neurocognitive Assessment in Clinical Trials of Patients With CNS TumorsJournal of Clinical Oncology, 2006
- Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2004
- Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain MetastasesJournal of Clinical Oncology, 2003
- Neurocognitive and Functional Assessment of Patients With Brain MetastasesAmerican Journal of Clinical Oncology, 2003
- Radiation injury and neurogenesisCurrent Opinion in Neurology, 2003
- Lead-In Phase to Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation for Patients With Brain Metastases: Centralized Assessment of Magnetic Resonance Imaging, Neurocognitive, and Neurologic End PointsJournal of Clinical Oncology, 2002
- Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04International Journal of Radiation Oncology*Biology*Physics, 2001
- Prognosis of patients treated for intracranial metastases with whole-brain irradiationAnnals of Medicine, 1998
- Radiation‐induced dementia in patients cured of brain metastasesNeurology, 1989
- Intracerebral metastases in solid-tumor patients: Natural history and results of treatmentCancer, 1981